# Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Bi

Source: https://onco.cc/trials/nct07483983/  
OnCo record `nct07483983` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of setidegrasib in pancreatic cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.

## Summary

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance is a phase 2, interventional study registered as NCT07483983 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 60 participants, started 2026-03-25 and due to reach its primary completion in 2027-09. Interventions recorded: ASP3082. Conditions listed: Metastatic/Locally Advanced Non-Small-Cell Lung Cancer; Metastatic/Locally Pancreatic Ductal Adenocarcinoma. Primary outcome: Evaluate the best overall response (BOR) based on investigator assessment per RECIST v1.1. Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: UNLOCK ASP3082
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07483983
- Phase: 2
- Setting: Phase 2, Multicenter, Open Label, Platform Study Investigating ASP3082 in Patients With Metastaic/Locally Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07483983: https://clinicaltrials.gov/study/NCT07483983

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- drugs: [Setidegrasib](https://onco.cc/drugs/setidegrasib/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07483983.json